Oxford BioTherapeutics Licenses Antibody to Sanofi-Aventis for Cancer Drug Development

The agreement calls for Sanofi-Aventis to make to OBT an undisclosed upfront cash payment, with OBT eligible for future development, regulatory, and performance milestone payments and royalties on worldwide product sales.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.